
Takeda’s stem cell treatment Alofisel flunks phase 3 trial in Crohn's complication
After trimming an early-stage Crohn’s disease candidate from i | After trimming an early-stage Crohn’s disease candidate from its pipeline this year, Takeda is dealing with the failure of another of its therapies in a related indication. Alofisel (daradstrocel), a stem cell therapy designed to...
This news is not good because phase 3 trials have failed.